Reversible Eltrombopag-Associated Bone Marrow Fibrosis With Hematologic Recovery After Drug Withdrawal in ASXL1-Mutated Hypoplastic Myelodysplastic Syndrome: A Case Report. (PubMed, EJHaem) - Sep 25, 2026 - "Careful reassessment of marrow morphology, clonal dynamics, and treatment-related niche perturbation may be warranted in patients with hypoplastic MDS who deteriorate during TPO-RA therapy. The authors have confirmed clinical trial registration is not needed for this submission."
Journal • Aplastic Anemia • Complement-mediated Rare Disorders • Fibrosis • Hematological Disorders • Hematological Malignancies • Immunology • Myelodysplastic Syndrome • Oncology • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases • ASXL1 • TET2
|
|
Chisato Ohe; Ikuo Matsuda; Kyoko Yoshihara; Mami Samori; Naru Tomigaki; Saki Takahashi; Satoshi Yoshihara; Yasuhito Nannya
|